Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.54 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6229111 | 1.00 | ADORA3 (0.54) | ADORA3ADORA1ADORA2AADORA2BPRMT5 | |
| SCHEMBL5534004 | 1.00 | ADORA3 (0.54) | ADORA3ADORA1ADORA2AADORA2BPRMT5 | |
| SCHEMBL6229115 | 1.00 | ADORA3 (0.54) | ADORA3ADORA1ADORA2AADORA2BPRMT5 | |
| Gw493838 SCHEMBL7192949 | 0.95 | ADORA3 (0.60) | ADORA3ADORA1ADORA2AADORA2BPRMT5 | |
| SCHEMBL6561807 | 0.91 | ADORA3 (0.51) | ADORA3ADORA1ADORA2AADORA2BPRMT5 | |
| SCHEMBL6561812 | 0.91 | ADORA3 (0.51) | ADORA3ADORA1ADORA2AADORA2BPRMT5 | |
| Gw493838 SCHEMBL6935807 | 0.87 | ADORA3 (0.66) | ADORA3ADORA1ADORA2AADORA2BPRMT5 | |
| Gw493838 SCHEMBL6250937 | 0.87 | ADORA3 (0.66) | ADORA3ADORA1ADORA2AADORA2BPRMT5 | |
| Gw493838 SCHEMBL6696560 | 0.87 | ADORA3 (0.66) | ADORA3ADORA1ADORA2AADORA2BPRMT5 | |
| Gw493838 SCHEMBL29384676 | 0.87 | ADORA3 (0.66) | ADORA3ADORA1ADORA2AADORA2BPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370569-B1 | PROCESS FOR PREPARING N6-SUBSTITUTED AMINOPURINE RIBOFURANOSE NUCLEOSIDES | GLAXO GROUP LTD (GB) | 2005-08-31 | — | — | EP | disclosed |
| US-20050176949-A1 | Process for preparing N6 substituted aminopurine ribofuranose nucleosides | GLAXO GROUP LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176949-A1 | Process for preparing N6 substituted aminopurine ribofuranose nucleosides | ADORA3, NUDT1, ADORA1 | ADORA3 1/4885ADORA1 3/4885ADORA2A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.